Alnylam Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Alnylam Pharmaceuticals (ALNY).

Price Target Range — 6 Quarters

Analyst Consensus — 23 Analysts

19Buy

4Hold

Consensus RatingBuy# Analysts23Avg. Consensus PT$382Upside to Avg. PT+139.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 2, 2026	Barclays	Eliana Merle	PT Cut	Overweight	$450→$380
Nov 2, 2026	Truist Securities	Danielle Brill	Downgrade	Buy→Hold	$315→$225
Nov 2, 2026	Canaccord Genuity	Whitney Ijem	PT Cut	Buy	$429→$323
Oct 30, 2026	UBS	Joon Lee	PT Cut	Buy	$354→$329
Oct 30, 2026	TD Cowen	Ritu Baral	PT Cut	Buy	$482→$354
Oct 30, 2026	Bernstein	Zhiqiang Shu	Downgrade	Outperform→Market Perform	$376→$199
Oct 30, 2026	Morgan Stanley	Michael Ulz	PT Cut	Equal-Weight	$300→$240
Oct 30, 2026	Goldman Sachs	Salveen Richter	PT Cut	Buy	$536→$320
Oct 30, 2026	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$253→$220
Oct 30, 2026	RBC Capital	Luca Issi	PT Cut	Outperform	$345→$280
Oct 30, 2026	Raymond James	Martin Auster	Downgrade	Strong Buy→Outperform	$420→$315
Oct 29, 2026	Needham	Joseph Stringer	PT Cut	Buy	$357→$243
Oct 15, 2026	UBS	Joon Lee	Assumes	Buy	$550→$354
Oct 14, 2026	Citigroup	Eric Joseph	PT Cut	Buy	$340→$320
Oct 14, 2026	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$256→$253
Oct 8, 2026	RBC Capital	Luca Issi	PT Cut	Outperform	$350→$345
Sep 30, 2026	JP Morgan	Jessica Fye	PT Cut	Overweight	$375→$369
Sep 21, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$455
Sep 8, 2026	Jefferies	Faisal Khurshid	PT Raise	Hold	$230→$260
Sep 2, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$455

Analyst Ratings News

PRO
Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $380

Barclays analyst Eliana Merle maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $450 to $380.

Benzinga Newsdesk

PRO
Truist Securities Downgrades Alnylam Pharmaceuticals to Hold, Lowers Price Target to $225

Truist Securities analyst Danielle Brill downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Buy to Hold and lowers the price target from $315 to $225.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $323

Canaccord Genuity analyst Whitney Ijem maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $429 to $323.

Benzinga Newsdesk

5 Stock Picks Last Month From Wall Street's Most Accurate Analysts

U.S. stocks fell Friday as Nasdaq dropped over 700 points; Benzinga highlighted top analysts’ latest calls on Allegro, Intel and Reddit.

Avi Kapoor

PRO
TD Cowen Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $354

TD Cowen analyst Ritu Baral maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $482 to $354.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $240

Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and lowers the price target from $300 to $240.

Benzinga Newsdesk

Alnylam Pharmaceuticals Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Alnylam Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $380

PRO
Truist Securities Downgrades Alnylam Pharmaceuticals to Hold, Lowers Price Target to $225

PRO
Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $323

5 Stock Picks Last Month From Wall Street's Most Accurate Analysts

PRO
TD Cowen Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $354

PRO
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $240

People Also Watch

People Also Watch

Alnylam Pharmaceuticals Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Alnylam Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $380

PROTruist Securities Downgrades Alnylam Pharmaceuticals to Hold, Lowers Price Target to $225

PROCanaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $323

5 Stock Picks Last Month From Wall Street's Most Accurate Analysts

PROTD Cowen Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $354

PROMorgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $240

People Also Watch

People Also Watch

PRO
Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $380

PRO
Truist Securities Downgrades Alnylam Pharmaceuticals to Hold, Lowers Price Target to $225

PRO
Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $323

PRO
TD Cowen Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $354

PRO
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $240